Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 15/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10272302 | 0.84 | HDAC6 (0.36) | HDAC6HDAC1MTOR | |
| SCHEMBL10247234 | 0.79 | HDAC8 (0.40) | HDAC6HDAC8HDAC1 | |
| SCHEMBL355960 | 0.77 | FGFR1 (0.39) | HDAC6HDAC8HDAC1 | |
| SCHEMBL10272388 | 0.75 | HDAC6 (0.38) | HDAC6HDAC1HDAC11HDAC3KDM1A | |
| SCHEMBL10104761 | 0.73 | HDAC6 (0.57) | HDAC6HDAC8HDAC1HDAC3 | |
| SCHEMBL10120339 | 0.72 | HDAC6 (0.64) | HDAC6HDAC8HDAC1HDAC3 | |
| SCHEMBL10120399 | 0.71 | HDAC6 (0.49) | HDAC6HDAC8HDAC1HDAC11HDAC3 | |
| SCHEMBL10120349 | 0.71 | HDAC6 (0.59) | HDAC6HDAC8HDAC1HDAC3 | |
| SCHEMBL10207683 | 0.71 | NPC1 (0.40) | HDAC6 | |
| SCHEMBL10272536 | 0.71 | CBLB (0.38) | HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778931-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | claimed |
| US-8778931-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778931-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778931-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20120165316-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165316-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165316-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| WO-2012088015-A2 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165316-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC5, HDAC1 | HDAC6 1/4885HDAC8 10/4885HDAC1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.